Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Evaluate Vantage Report: US Approvals Under the Spotlight
On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose confirmatory trials have failed. Will the US FDA's standards change after years of apparent leniency? 'US Approvals Under the Spotlight', the latest report from Evaluate Vantage,…
Report library
Evaluate Pharma Orphan Drug Report 2020
What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking. Following a difficult end to 2018, the biopharma industry recovered…
Evaluate Vantage 2020 Preview
The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2019
Mega-deals mask a significant decline in M&A activity for pharma and medtech The Evaluate Vantage Half-Year Review 2019 summaries the most significant trends across…
EvaluatePharma World Preview 2019, Outlook to 2024
Worldwide prescription drugs sales predicted to reach $1.18trn in 2024, with a compound annual growth of 6.9%, significantly higher than the 1.7% CAGR between…
